Pharma’s Interest in Lexicon’s LX4211 May Grow After J&J’s Favorable Invokana FDA Panel
Lexicon may be able to secure a partner for diabetes drug LX4211 following the favorable review of Johnson & Johnson’s Invokana by a panel that met to advise the FDA ahead of its decision on approval.
The company has said it wants to seal a partnership for the drug before launching Phase III trials, which it hopes to initiate in the first half of the year. Jeffrey L. Wade, Executive Vice President and Chief Financial Officer, recently commented that Lexicon is pleased with the process and progression of talks, which involve discussions regarding different types of deal structures.
Both LX4211 and Invokana belong to a class of drugs known as SGLT-2 inhibitors. LX4211 also targets SGLT-1 and is the first dual inhibitor of this target in development for diabetes.